Clinical Trial

CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated August 9, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-08-17; most recent amendment 2024-08-06.
Trial Details
NCT Number NCT06006390
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Collaborators: Shanxi Bethune Hospital
Conditions Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer, Pancreas Cancer, Lung Cancer, Breast Cancer
Enrollment 60 participants
Start Date 2023-09-07
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-09